NASDAQ:RXII - RXi Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.88
+0.30 (1.20%)
Get New RXi Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RXII and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RXII

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for RXi Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.88.

This chart shows the closing price for RXII for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in RXi Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/15/2018HC WainwrightReiterated RatingBuyLow
8/15/2018HC WainwrightSet Price TargetBuy$3.00High
8/2/2018HC WainwrightSet Price TargetBuy$3.00Medium
7/16/2018HC WainwrightSet Price TargetBuy$3.00Low
7/9/2018HC WainwrightInitiated CoverageBuy$3.00High
(Data available from 1/19/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/19/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
RXi Pharmaceuticals logo
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
Read More

Today's Range

Now: $0.88
Low: $0.85
High: $0.90

50 Day Range

MA: $0.42
Low: $0.36
High: $0.50

52 Week Range

Now: $0.88
Low: $0.31
High: $7.70

Volume

161,219 shs

Average Volume

1,725,006 shs

Market Capitalization

$3.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07

Frequently Asked Questions

What sell-side analysts currently cover shares of RXi Pharmaceuticals?

The following Wall Street research analysts have issued reports on RXi Pharmaceuticals in the last year:
View the latest analyst ratings for RXII.

What is the current price target for RXi Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for RXi Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for RXi Pharmaceuticals in the next year.
View the latest price targets for RXII.

What is the current consensus analyst rating for RXi Pharmaceuticals?

RXi Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for RXII.

How do I contact RXi Pharmaceuticals' investor relations team?

RXi Pharmaceuticals' physical mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The biotechnology company's listed phone number is (508) 767-3861 and its investor relations email address is [email protected] The official website for RXi Pharmaceuticals is www.rxipharma.com.